Malignant Hematology

For over 20 years, we have been working to make a difference for people diagnosed with lymphoma. We continue to invest in innovative therapies that meet each patient's unique needs and strive for the best possible outcomes.

Roche's medicines have helped improve the treatment of lymphoma. But there is still more to be done to help as many people as possible live longer, healthier lives.

We focus particularly on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In DLBCL, we work to increase the chances of cure for newly diagnosed patients, reduce the risk of relapse, and offer innovative treatment options for those who relapse. For FL, the goal is to enable long term remissions, even after multiple lines of treatment, and to minimize the impact of treatment on quality of life.

In addition to developing new therapies, we are also working on solutions beyond drugs, such as improving access to treatment, so that more people with lymphoma can be offered the best possible care.

M-PK-00002494